people buying at .7c are paying a 5% premium on a post consolidation price of 2c - and that if the market agrees with the EV being put forward:
Post-acquisition of Botanix and post A$3m Capital Raising, BNE to have market capitalisation of ~$7.6 million with cash of ~$3.6 million, resulting in an enterprise value of ~$4.0 million.
sp may rise if there are good news on the clinical trials and an investor presentation showing a clear path to commercialization and revenues, otherwise it's hard to see short term increase in the sp
Ann: Acquisition of Botanix Pharmaceuticals Inc, page-13
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.015(4.05%) |
Mkt cap ! $690.6M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $1.421M | 3.726M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 74685 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 42680 | 5 |
View Market Depth
| Last trade - 15.59pm 10/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |